

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

February 3, 2018

To B S E Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001 To The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E) Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB

Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Un-audited financial results for the quarter ended December 31, 2017, published in Financial Express and Andhra Prabha on February 3, 2018, for your reference.

Thanking you,

Yours faithfully, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl: as above

NEULAND LABORATORIES LIMITED

Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2017

	STREET STATE	(Amount in lakhs of ϵ , unless otherwise stated)				
SI.	Quarter Ended			Nine Mont	hs Ended	
Partículars	31.12.2017 (Unaudited)	30.09.2017 (Unaudited)	31.12.2016 (Unaudited)	31.12.2017 (Unaudited)	31.12.2016 (Unaudited)	
1 Revenue			TO A STATE OF	TO SOUTH SERVICE	10 m	
(a)Revenue from operations (b)Other income	11,593.17 135.21	12,585.49 33.63	13,460.10 28.78	35,926.73 434.74	43,804.73 80.18	
Total Income	11,728.38	12,619.12	13,488.88	36,361.47	43,884.91	
- Pubelises				SEAL STREET	THE BEST	
(a)Cost of materials consumed	7,055.59	7,151.48	6,503.21	20,210.09	20,345.60	
(b)Excise duty		1000	216.72	172.79	625.88	
(c)Changes in inventories of finished goods and work-in-progress	(1,630.68)	(1,640.22)	100.05	(4,346.24)	813.18	
(U)Employee benefits expense	1,963.55	1,986.96	1,628.92	5,862.75	4,863.26	
(e)Finance costs	481.22	523.19	506.14	1,480.98	1,691.30	
(f)Depreciation and amortisation expense	553.51	538.34	481.85	1,602.07	1,372.34	
(g)Manufacturing expenses	1,647.99	1,914.71	1,437.74	5,500.65	4,484.67	
(h)Other expenses	1,568.83	1,736.38	2,052.64	5,038.88	6,184.00	
Total Expenses	11,640.01	12,210.84	12,927.27	35,521.97	40,380.23	
1. One perole rax [1-2]	88.37	408.28	561.61	839.50	3,504.68	
lax expense		1	1946000	Control Salar	THE THE STATE OF	
(a)Current tax	(42.89)	194.83	329.05	336.69	1,318.93	
(b)Deferred tax benefit	10.50	(45.99)	(130.69)	(107.17)	(151.48	
Profit for the period (3-4)	120.76	259.44	363.25	609.98	2,337.23	
Other comprehensive income (net of taxes)	THE RESERVE TO THE RE	BUT DEMOST	NO SU PARTE	Co of Village	- 100	
(a) items that will not be reclassified to profit or loss	2017 12 70 50 10	GET SUBJECT BAD	TENER SERVED		San Design	
(1) Ke-measurement losses on defined benefit plans	(5.55)	(5.56)	(5.56)	(16.67)	(16.67	
(D) Items that will be reclassified to profit or loss	(5.55)	(5.55)	(5,50)	all Laborator	100000000000000000000000000000000000000	
lotal comprehensive income	115.21	253.88	357.69	593.31	2,320.56	
Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49	895.49	
Lainings Per Share(of ₹10 each) (In absolute ₹ terms)	0,0.17	0,5,4,5	0,3.3,			
(d)Basic (refer note 6)	1.36	2.92	4.09	6.87	26.31	
(b)Diluted (refer note 6)	1.36	2.92	4.09	6.87	26.31	

e accompanying notes to the financial results

NOTES:

- 1 The unaudited standalone financial results for the quarter ended 31 December 2017 and year to date result for the period 1 April 2017 to 31 December 2017, have been reviewed by the Audit Committee in their meeting held on 1 February 2018, approved and taken on record of the Board by the Board of Directors at their meeting held on 2 February 2018. These results have been subjected to a "Limited Review" by the Statutory Auditors of the Company.
- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of
- 3 The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and nine months ended 31

Particulars		Quarter Ended 31.12.2016	Amount (z in lakhs) Nine Months Ended 31.12.2016
Net profit under previous GAAP	district to shape	381.25	2,391,25
Interest on borrowings from related parties	and that I will a	(21.07)	(63.22)
Recognition of rental income at fair value	Service of Trebell	3.48	10.43
Remeasurement of employee benefits	THE RESERVE OF THE PERSON	(4.48)	(13.44)
Others		(5,46)	(16.38)
Deferred tax benefit		9.53	28.59
Total net profit for the period under Ind AS	A.T. T. A.T.	363.25	2,337.23
Other comprehensive income		(5.56)	(16.67)
Total comprehensive income	SEX MAIN	357.69	2,320.56

- 5 In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent company Neuland Health Sciences
 Private Limited (NHSPL) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSPL and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSPL and it shall allot the fresh equity share capital to the shareholders of NHSPL and NPRPL in the following ratio duly determined by independent
- -552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSPL of ₹10 each, fully paid up and;
- -410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.

As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals from the National Company Law Tribunal Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final approval from Nationa Company Law Tribunal and to comply with the Listing (Obligations and Disclosures) Regulations, 2015, the accompanying statement for the quarter and nine months ended 31 December 2017 have been prepared without giving any effect of the proposed amalgamation.

- EPS for the quarters and nine months period is not annualized.
- Revenue from operations for the quarter and nine months ended 31 December 2017 is not comparable with revenue from operations of the corresponding quarter of the previous year and nine months ended 31 December 2016 as these periods include amount of excise duty which is not included for the quarter ended 31 December 2017 after implementation of Goods and Service Tax.

By Order of the Board For Neuland Laboratories Limited

NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 201

SI.		(Amount in lakhs of \(\tau\), unless otherwise stated)				
No.	Particulars	Quarter Ended			Nine Months Ended	
		31.12.2017 (Unaudited)	30.09.2017 (Unaudited)	31.12.2016 (Unaudited)	31.12.2017 (Unaudited)	31.12.2016
	Revenue			(ondudited)	(Ollaudited)	(Unaudited)
	(a)Revenue from operations	11,593.17	12,585.49	12 460 40	25 024 20	
	(b)Other income	135.21	33.63	13,460.10	35,926.73	43,804.73
2	Total Income	11,728.38	12,619.12	28.78	434.74	80.18
4	Expenses	11,720.30	12,019.12	13,488.88	36,361.47	43,884.91
	(a)Cost of materials consumed	7,055.59	7 151 40	1 500 04	20.010.00	
	(b)Excise duty		7,151.48	6,503.21	20,210.09	20,345.60
	(c)Changes in inventories of finished goods and work-in-progress	(1,630.68)	14 640 221	216.72	172.79	625.88
	I descriptoyee benefits expense	1,963.55	A SANCE AND THE RESIDENCE AND THE PARTY OF T	100.05	(4,346.24)	813.18
	(e)Finance costs	481.22	1,986.96 523.19	1,628.92 506.14	5,862.75	4,863.26
	(f)Depreciation and amortisation expense	553.51	538.34	481.85	1,480.98	1,691.30
	(g)Manufacturing expenses	1,647.99	1,914.71	1,437.74	1,602.07	1,372.34
	(h)Other expenses	1,568.83			5,500.65	4,484.67
	Total Expenses		1,736.38	2,052.64	5,038.88	6,184.00
3	Profit before tax (1-2)	11,640.01	12,210.84	12,927.27 561.61	35,521.97	40,380.2
4	Tax expense	00.37	408.28	301.01	839.50	3,504.6
-	(a)Current tax	(42.00)	404.02	220.05	****	
	(b)Deferred tax benefit .	(42.89)		329.05	336.69	1,318.9
5	Profit for the period (3-4)	10.50	(45.99)	(130.69)	(107.17)	(151.4)
5	Other comprehensive income (net of taxes)	120.76	259.44	363.25	609.98	2,337.2
	(a) Items that will not be reclassified to profit or loss		CONTRACTOR OF THE PARTY OF THE		Contract of the second	
	(i) Re-measurement losses on defined benefit plans	-		15.50		9 Jan 3 1 1 3
	(b) Items that will be reclassified to profit or loss	(5.55)	(5.56)	(5.56)	(16.67)	(16.6
	Total comprehensive income		-			
-	Paid-up Equity Share Capital (Caramata Caramata)	115.21	253.88	357.69	593.31	2,320.5
	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49	895.4
	Earnings Per Share(of ₹10 each) (In absolute ₹ terms)	- A	THE TOTAL STATE OF THE PARTY OF		THE STREET	THE PARTY NAMED IN
1	(a)Basic (refer note 6)	1.36	2.92	4.09	6.87	26.3
	(b)Diluted (refer note 6)	1.36	2.92	4.09	6.87	76.3

See accompanying notes to the financial results

- The unaudited standalone financial results for the quarter ended 31 December 2017 and year to date result for the period 1 April 2017 to 31 December 2017, have been reviewed by the Audit Committee in their meeting held on 1 February 2018, approved and taken on record of the Board by the Board of Directors at their meeting held on 2 February 2018. These results have been subjected to a "Limited Review" by the Statutory Auditors of the Company
- 2 The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of
- The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- 4 Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and nine months ended 31

Particulars	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016		
Net profit under previous GAAP Interest on borrowings from related parties Recognition of rental income at fair value Remeasurement of employee benefits	381.25 (21.07) 3.48 (4.48) (5.46)	2,391.25 (63.22) 10.43 (13.44) (16.38)		
Others Deferred tax benefit Total net profit for the period under Ind AS	9.53 363.25	28.59 2,337.23 (16.67)		
Other comprehensive income Total comprehensive income	(5.56) 357.69	2,320.56		

- 5 In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent co Private Limited (NHSPL) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSPL and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSPL, and it shall allot the fresh equity share capital to the shareholders of NHSPL and NPRPL in the following ratio duly determined by independent
- 552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSPL of ₹10 each, fully paid up and;
- 410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.

As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, As at the date of approval or this statement, the scheme or amaigamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals from the National Company Law Tribunal. Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final approval from National Company Law Tribunal and to comply with the Listing (Obligations and Disclosures) Regulations, 2015, the accompanying statement for the quarter and nine months ended 31 December 2017 have been prepared without giving any effect of the proposed amaigamation.

- EPS for the quarters and nine months period is not annualized.
- Revenue from operations for the quarter and nine months ended 31 December 2017 is not comparable with revenue from operations of the Revenue from operations for the quarter and fine months ended 31 December 2017 is not comparable with revenue from operations of the corresponding quarter of the previous year and nine months ended 31 December 2016 as these periods include amount of excise duty which is not included for the quarter ended 31 December 2017 after implementation of Goods and Service Tax.

 By Order of the December 2017 after implementation of Goods and Service Tax.

For Neuland Laboratories Limited